Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis, AstraZeneca Cede Seed Business: Two Pharma Pure Plays Created

Executive Summary

The Novartis/AstraZeneca agribusiness spin-off reflects the "limited" synergies between the agricultural and pharmaceutical businesses, the two companies maintained.

You may also be interested in...



Aventis Decision On Ag Business Expected Within 18 Months

Aventis expects to make a decision on carrying forward with its agricultural business component in 2001, Investor Relations Director Arvind Sood said during a July 28 conference call.

Aventis Decision On Ag Business Expected Within 18 Months

Aventis expects to make a decision on carrying forward with its agricultural business component in 2001, Investor Relations Director Arvind Sood said during a July 28 conference call.

Novartis Rx Exec Changes Include U.S. COO Epstein To Oncology Unit Head

Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.

Related Content

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel